Grant: Master's Award: Canada Graduate Scholarships
McGill University
$17,500.00
Efficacy, toxicity, and delivery methods of therapeutic ribonucleic acids (RNAs) for use in human immunodeficeincy virus (HIV) stem cell therapy
EF 2017-18
Résumé
According to the World Health Organization, HIV infects over 36 million individuals. Currently, antiretroviral therapies (ART) are available to control HIV replication and prevent disease progression, but cannot cure the infection. The use of stem cell therapy to cure HIV infection represents a promising alternative to ART. In 2007, a bone marrow cell transplant from an HIV-resistant donor to an infected individual was reported to cure the infection. However, same-blood-type donors are rare and high mortality rates are associated with cell transplants between individuals. Alternatively, HIV-infected patients could undergo cell transplants using their own cells that have been isolated and modified to acquire HIV resistance.Therapeutic RNAs have been designed to confer HIV resistance and can be permanently expressed in a patient's cells using virus delivery tools based on HIV. A major challenge is that many effective therapeutic RNAs also target the production of these delivery tools. One aim for my project is therefore to optimize the virus delivery tools that can be used in further studies characterizing anti-HIV RNAs as well as in stem cell therapy clinical trials.Also, while several candidate RNAs have been identified, few studies have compared the effects of candidates from different classes of RNAs. Another aim for my project is therefore to compare the efficacy and toxicity of top RNA candidates in various human cell lines. These results will help determine which RNA molecules have the highest clinical potential for use in HIV stem cell therapy.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
386550
Name
Malard Camille
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Efficacy, toxicity, and delivery methods of therapeutic ribonucleic acids (RNAs) for use in human immunodeficeincy virus (HIV) stem cell therapy
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Anti-Hiv Rnas; Cell Viability Assays; Flow Cytometry; Hiv Stem Cell Therapy; Hiv/Aids Cure; Lentiviral Delivery Systems; Molecular Cloning; Potency And Toxicity Screens; Screens For Immune Activation; Western Blots
Abstract
According to the World Health Organization, HIV infects over 36 million individuals. Currently, antiretroviral therapies (ART) are available to control HIV replication and prevent disease progression, but cannot cure the infection. The use of stem cell therapy to cure HIV infection represents a promising alternative to ART. In 2007, a bone marrow cell transplant from an HIV-resistant donor to an infected individual was reported to cure the infection. However, same-blood-type donors are rare and high mortality rates are associated with cell transplants between individuals. Alternatively, HIV-infected patients could undergo cell transplants using their own cells that have been isolated and modified to acquire HIV resistance.Therapeutic RNAs have been designed to confer HIV resistance and can be permanently expressed in a patient's cells using virus delivery tools based on HIV. A major challenge is that many effective therapeutic RNAs also target the production of these delivery tools. One aim for my project is therefore to optimize the virus delivery tools that can be used in further studies characterizing anti-HIV RNAs as well as in stem cell therapy clinical trials.Also, while several candidate RNAs have been identified, few studies have compared the effects of candidates from different classes of RNAs. Another aim for my project is therefore to compare the efficacy and toxicity of top RNA candidates in various human cell lines. These results will help determine which RNA molecules have the highest clinical potential for use in HIV stem cell therapy.
Competitiondate
201712
Approvedterm2
1 yr 0 mth
Pinamesdelim
Malard, Camille
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~